drugset / Trial / NCT00017693

Recombinant Human IL-4 Receptor Used in Treatment of Asthma

NCT00017693 ↗

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose is to measure the effectiveness of recombinant human interleukin-4 receptor (IL-4R) in treating asthma. Asthma can be caused by the allergic response from breathing in certain irritants. Interleukin 4 (IL-4), which is naturally produced by the body, plays a major role in this allergic response. Doctors feel that IL-4 activity may be stopped by giving IL-4R, a product that binds to IL-4, and thereby decrease the problems of asthma.

Timeline

Start
1998-05
Primary completion
2000-02
Completion
2000-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Recombinant human soluble IL-4 receptor Unknown 0.75 mg Inhaled
Subject Recombinant human soluble IL-4 receptor Unknown 1.5 mg Inhaled
Subject Recombinant human soluble IL-4 receptor Unknown 3 mg Inhaled

Indications